Skip to main content

Table 1 Patient demographics

From: Milan criteria in the MELD era—is it justifiable to extend the limits for orthotopic liver transplantation?

  [All], N = 120 Number
Age 61 [54.7; 65.4] 120
 < 65 91 (75.8%)
 > 65 29 (24.2%)
Sex 120
 F 22 (18.3%)
 M 98 (81.7%)
Disease
 ALD 75 (62.5%)
 HCV 14 (11.7%)
 HBV 7 (5.8%)
 Cryptogen 12 (10%)
 Other 12 (10%)
AFP (ng/ml) 8.00 [4.10; 70.0] 105
Waiting_time (days) 212 [72.5; 347] 120
D (mm) 33.2 (20.8) 120
MELD 11 [8; 15] 97
 MELD ≤ 15 71 (73.2%)
 MELD = 15–30 17 (17.5%)
 MELD > 30 9 (9.28%)
preTreat 120
 No pre-treatment 45 (37.5%)
 Pre-treatment 75 (62.5%)
N 100
N = 1 59 (59.0%)
N = 1–3 30 (30.0%)
N > 3 11 (11.0%)
Grade 59
 1 23 (39.0%)
 2 33 (55.9%)
 3 3 (5.08%)
Asan 120
 Exceeding 35 (29.2%)
 Fulfilling 85 (70.8%)
AFP score 105*
 > 2 26 (24.8%)
 ≤ 2 79 (75.2%)
MC 120
 Exceeding 46 (38.3%)
 Fulfilling 74 (61.7%)
UTS 120
 Exceeding 34 (28.3%)
 Fulfilling 86 (71.7%)
  1. ALD alcoholic liver disease, HCV hepatitis C virus, HBV hepatitis B virus, AFP alpha-feto protein in ng/ml, D diameter of the largest tumor in mm, MELD model of end-stage liver disease, N number of tumors, MC Milan criteria, UTS up-to-seven criteria
  2. *Missing AFP values for 15 patients. Data are shown as the average and standard deviation (round brackets) for normally distributed data and as the median and quantiles (square brackets) for non-normally distributed data